Form 4: Tarsus COO Sells Shares for Tax Obligations

Tarsus Pharmaceuticals' Chief Operating Officer, Seshadri Neervannan, sold shares to cover tax withholding obligations related to RSU vesting.

Summary

• Seshadri Neervannan, Chief Operating Officer of Tarsus Pharmaceuticals, Inc. (TARS), reported sales of common stock.
• The sales occurred on March 17, 2026, March 18, 2026, and March 19, 2026.
• A total of 11,324 shares were sold across these three dates (3,125, 3,610, and 4,589 shares respectively).
• The shares were sold at prices ranging from $67.00 to $69.42 per share.
• The purpose of these sales was to cover tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs).
• The filing explicitly states that these sales were mandated by the Issuer's 'sell to cover' policy and were not discretionary transactions by the Reporting Person.
• Following these transactions, Seshadri Neervannan directly beneficially owns 85,780 shares of common stock.
• An additional 475 shares are indirectly owned by his daughter, for which the Reporting Person disclaims beneficial ownership.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. The reported transactions are non-discretionary sales to cover tax obligations, which is a routine event and does not reflect a change in management's outlook or a strategic move.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions, where an executive sells shares to satisfy tax obligations upon RSU vesting, are a common and routine occurrence in the pharmaceutical industry and across publicly traded companies. These transactions are typically non-discretionary and are not usually interpreted as an indicator of management's sentiment regarding the company's future prospects or stock performance.

Stakeholder Impact

• Shareholders: Minimal impact, as these are routine, non-discretionary sales for tax purposes and do not signal a change in company fundamentals or management's confidence.

Key Dates

Recommendation

The filing details a routine 'sell to cover' transaction by a company executive to satisfy tax obligations from RSU vesting. This is a non-discretionary event and does not provide new information that would alter the fundamental investment thesis for Tarsus Pharmaceuticals. Therefore, a 'hold' recommendation is appropriate as this event is neutral to the company's valuation and prospects.

Keywords

Tarsus Pharmaceuticals, TARS, Form 4, Insider Transaction, Restricted Stock Units, RSU, Sell to Cover, Tax Withholding, Seshadri Neervannan